Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Laquinimod Stories

2013-11-30 23:03:24

MarketReportsOnline.com offers “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)” research that analyzes the global market sizing and growth of multiple sclerosis in terms of revenue, number of patients and sales of effective drugs. Dallas, Texas (PRWEB) November 30, 2013 The report titled "Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)" provide an insight into the market dynamics and various trends and opportunities associated...

2013-07-14 23:00:54

Transparency Market Research add new "Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018" market research report to its report store. Browse the report: visit http://www.transparencymarketresearch.com/multiple-sclerosis-drugs.html Albany, New York (PRWEB) July 14, 2013 Multiple sclerosis (MS) is an inflammation of fatty myelin sheaths around the axons of the brain and spinal cord. MS tends to affect the ability of...

2011-12-08 07:57:27

(Ivanhoe Newswire) — Save the neurons! A new study suggests laquinimod triggers immune cells within the central nervous system produce and release brain-derived neurotrophic factor, BDNF, contributing to the repair or survival of neurons; therefore limiting brain damage. Laquinimod is an orally available synthetic compound for the treatment of relapsing-remitting multiple sclerosis. "Our data are indicative of a direct and sustained effect of laquinimod on the up-regulation of...

2011-12-06 11:21:42

Results published in the American Journal of Pathology Laquinimod is an orally available synthetic compound that has been successfully evaluated in phase II/III clinical studies for the treatment of relapsing-remitting multiple sclerosis (RRMS). The mechanism of action of laquinimod has not been fully elucidated, but a study published in the January 2012 issue of The American Journal of Pathology suggests that laquinimod triggers immune cells within the central nervous system to produce...

2011-06-28 00:00:33

This report provides perspective on the MS landscape in light of Merck Serono's decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Multiple Sclerosis," designed to provide critical strategic insight for pharma and biotech companies with a stake in the...

2011-04-15 08:14:38

(Ivanhoe Newswire) -- The drug laquinimod reduced the number of instances in relapses for individuals with multiple sclerosis (MS) in a long-term, phase III clinical study involving 1,106 participants with relapsing-remitting MS in 24 countries. Participants in the study received either a once-daily oral dose of 0.6 milligrams of laquinimod or a matching placebo for exactly two years. 80 percent of those taking laquinimod and 77 percent of those taking the placebo completed the two-year...

2008-11-06 03:00:20

Lund, Sweden, November 6, 2008 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at the New York Palace Hotel in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided. The presentation will include the Phase III projects laquinimod, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, which is licensed...

2008-10-28 09:00:07

Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*. In a completed Phase Ib trial twelve patients have been treated for 84 days at various dose levels of ABR-215757. The maximum tolerable dose (MTD) for ABR-215757 was defined as 4.5 mg/day. The overall safety profile throughout the...

2008-10-17 03:00:16

Lund, Sweden, October 17, 2008 - Active Biotech AB's (NASDAQ OMX Nordic: ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) today announce information regarding the candidate drug RhuDex(R) for the treatment of rheumatoid arthritis. RhuDex(R) will be examined in a further series of laboratory tests, under the auspices of the UK MHRA (Medicines and Healthcare products Regulatory Agency). These in-vitro studies will examine any potential detrimental interactions between...

2008-09-19 12:00:36

Teva Pharmaceutical Industries has reported new data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis, which demonstrated a significant reduction in the mean number of gadolinium-enhancing lesions in both patients who switched from placebo to laquinimod and patients who continued with their initial laquinimod dose. In relapsing-remitting multiple sclerosis patients who switched from placebo to laquinimod, 52% reduction in the mean number of GdE lesions...